GLUE Jul 2024 2.500 call
| Previous close | 0.9300 |
| Open | 0.9300 |
| Bid | 0.0000 |
| Ask | 3.9000 |
| Strike | 2.50 |
| Expiry date | 2024-07-19 |
| Day's range | 0.9300 - 0.9300 |
| Contract range | N/A |
| Volume | |
| Open interest | 43 |
GlobeNewswireMonte Rosa Therapeutics Provides Development Progress Updates on MRT-2359 and MRT-6160
Ongoing Phase 1/2 Study of MRT-2359 for MYC-driven solid tumors demonstrates favorable safety and pharmacodynamic profile dosing 0.5 mg using a 21/7 schedule; currently assessing 0.75 mg dose level; final determination of recommended Phase 2 dose and updated clinical results anticipated in H2 2024 IND submission achieved for MRT-6160, a VAV1-directed MGD in development for systemic and neurological autoimmune diseases; initiation of Phase 1 SAD/MAD study expected this summer with Phase 1 clinica
- GlobeNewswire
Monte Rosa Therapeutics Presents Preclinical Data at EULAR 2024 Demonstrating Therapeutic Potential of MRT-6160 for the Treatment of Rheumatoid Arthritis
MRT-6160, a VAV1-directed molecular glue degrader (MGD), inhibits disease progression, pro-inflammatory cytokines and autoantibody production in a model of rheumatoid arthritis Initiation of MRT-6160 Phase 1 SAD/MAD study anticipated in mid-year 2024 with initial clinical data expected in Q1 2025 Poster presentation today at 14:45 CET / 8:45 a.m. ET BOSTON, June 14, 2024 (GLOBE NEWSWIRE) -- Monte Rosa Therapeutics, Inc. (Nasdaq: GLUE), a clinical-stage biotechnology company developing novel mole
Simply Wall St.Institutional investors own a significant stake of 40% in Monte Rosa Therapeutics, Inc. (NASDAQ:GLUE)
Key Insights Institutions' substantial holdings in Monte Rosa Therapeutics implies that they have significant influence...
